Table 1.
Baseline characteristics (N = 187).
| Characteristic | N (%) |
|---|---|
| Age (median, IQR) | 67 (59–73) |
| Sex | |
| Female | 99 (52.9) |
| Male | 88 (47.1) |
| ECOG PS | |
| 0 | 70 (37.4) |
| 1 | 102 (54.5) |
| 2 | 15 (8.0) |
| Smoking, pack-years (median, IQR) | 35 (15–50) |
| Cardiovascular comorbidity | 94 (50.3) |
| Coronary artery disease | 34 (18.2) |
| Pulmonary comorbidity | 78 (41.7) |
| Cardiovascular or pulmonary comorbidities | 127 (67.9) |
| CCI (median, IQR) | 3 (2–4) |
| 0–2 (low) | 66 (35.3) |
| 3–4 (intermediate) | 78 (41.7) |
| 5–9 (high) | 43 (23.0) |
| Histology | |
| Adenocarcinoma | 147 (78.6) |
| Squamous cell carcinoma | 29 (15.5) |
| Other | 11 (5.9) |
| AJCC Stage (7th edition) | |
| IIA-B | 4 (2.1) |
| IIIA | 119 (63.6) |
| IIIB | 62 (33.2) |
| IV (oligometastatic) | 2 (1.1) |
| T stage | |
| x, 1–2 | 108 (57.8) |
| 3–4 | 79 (42.2) |
| N stage | |
| 0–2 | 144 (77.0) |
| 3 | 43 (23.0) |
| Left-sided primary | 74 (39.6) |
| RT dose, Gy (median, IQR) | 66.6 (66.6–66.6) |
| RT technique | |
| Proton therapy | 98 (52.4) |
| PBS-PT | 9 (4.8) |
| PS-PT | 89 (47.6) |
| Photon therapy | 89 (47.6) |
| IMRT | 68 (36.4) |
| 3D-CRT | 21 (11.2) |
| Internal target volume (cc; median, IQR) | 242.9 (165.3–427.2) |
| Mean heart dose (Gy; median, IQR) | 8.1 (4.8–17.8) |
| Mean lung dose (Gy; median, IQR) | 16.8 (13.5–19.3) |
| Chemotherapy regimen | |
| Carboplatin/paclitaxel | 106 (56.7) |
| Cisplatin/etoposide | 57 (30.5) |
| Other | 24 (12.8) |
| Chemotherapy sequence | |
| Concurrent | 184 (98.4) |
| Sequential | 3 (1.6) |
IQR, interquartile range; PS, performance status; CCI, Charlson Comorbidity Index; RT, radiotherapy; PT, proton therapy; PBS, pencil beam scanning; PS, passive scattering; IMRT, intensity-modulated radiotherapy; 3D-CRT, 3-dimensional conformal radiotherapy.